文献速递慢性静脉疾病

大隐静脉功能不全介入治疗的长期结局:随机对照试验网状Meta分析

Network meta-analysis of randomized controlled trials evaluating long-term outcomes of interventional approaches for great saphenous vein insufficiency.
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2026-06-15

该网状Meta分析纳入33项随机对照试验的7913例大隐静脉功能不全患者,比较不同介入方式的长期疗效与安全性。结果显示,在CEAP C2-C5患者中,高位结扎剥脱术的长期无失败率显著高于氰基丙烯酸酯闭合、1470nm静脉激光消融和射频消融;微创介入术后恢复正常活动更快。

要点

  • CEAP C2-C5患者中,高位结扎剥脱术长期无失败率显著优于氰基丙烯酸酯闭合、EVLA-1470nm和射频消融。
  • 微创介入(EVLA-1470、EVLA-810、电凝)术后恢复正常活动时间短于高位结扎剥脱术。
  • 高位结扎剥脱术瘀斑和感染比例较高,消融手术皮肤色素沉着比例较高。

核心结论

  • 在CEAP C2-C5患者中,高位结扎剥脱术提供更高的长期无失败率和静脉临床严重程度评分改善,而微创介入提供更快的短期恢复。

研究设计与样本

  • 网状Meta分析,遵循PRISMA-NMA清单,检索PubMed、Scopus、Cochrane CENTRAL、ProQuest和Web of Science至2025年7月11日。
  • 纳入33项随机对照试验的47篇报告,共7913例大隐静脉功能不全患者。
  • 采用Kaplan-Meier和log-rank检验评估无失败率,个体患者数据从已发表KM曲线重建;临床结局采用频率学网状Meta分析(DerSimonian-Laird随机效应模型);并发症采用广义线性混合模型进行Meta比例分析。

主要发现

  • 高位结扎剥脱术的长期无失败率显著高于氰基丙烯酸酯闭合(HR 1.98;95%CI 1.24-3.16;P<.001)、EVLA-1470nm(HR 2.37;95%CI 1.38-4.06;P<.001)和射频消融(HR 2.64;95%CI 1.69-4.12;P=.002)。
  • 电凝在6个月时静脉临床严重程度评分最低(均数差-0.59;95%CI -1.11至-0.06;P=.03)。
  • 微创介入(EVLA-1470,P<.001;EVLA-810,P=.02;电凝,P=.006)术后恢复正常活动快于高位结扎剥脱术。
  • 高位结扎剥脱术瘀斑比例为76.37%、感染比例为2.35%;消融手术皮肤色素沉着比例为4.34%-11.41%。

临床怎么用

  • 对于CEAP C2-C5的大隐静脉功能不全患者,选择治疗方式时应权衡长期疗效与短期恢复:高位结扎剥脱术长期无失败率更高,微创介入恢复更快。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Great saphenous vein (GSV) insufficiency is a major contributor to chronic venous disease, associated with substantial morbidity and reduced health status. Although various surgical and minimally invasive interventions are available, their long-term efficacy, safety, and recovery profiles remain uncertain. Therefore, this study aims to provide comprehensive evidence to guide clinical decision-making and optimize interventional strategies for GSV insufficiency. METHODS: This network meta-analysis (NMA) was performed following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses-NMA checklist of items. Comprehensive searches were conducted on PubMed, Scopus, Cochrane Central Register of Controlled Trials, ProQuest, and Web of Science from inception to July 11, 2025. Data analyses were performed using RStudio version 4.5.1 (Posit Software). Kaplan-Meier (KM) and log-rank test were applied to evaluate freedom from failure, with individual patient data reconstructed from published KM curves. Clinical outcomes were synthesized using a Frequentist NMA with DerSimonian-Laird random-effects model. Complications were analyzed using meta-proportions with a generalized linear mixed model at the latest follow-up. RESULTS: A total of 7913 cases of GSV insufficiency from 47 reports from 33 randomized controlled trials were included. KM and log-rank analyses revealed that high ligation and stripping (HL&S) had a significantly higher long-term freedom from failure compared with cyanoacrylate closure [hazard ratio (HR), 1.98; 95% confidence interval (CI), 1.24-3.16; P < .001], endovenous laser ablation (EVLA)-1470 nm (HR, 2.37; 95% CI, 1.38-4.06; P < .001), and radiofrequency ablation (HR, 2.64; 95% CI, 1.69-4.12; P = .002) among patients with Clinical-Etiology-Anatomy-Pathophysiology C2-C5 Classification. Regarding clinical outcomes, electrocoagulation (mean difference, -0.59; 95% CI, -1.11 to -0.06; P = .03) showed lowest Venous Clinical Severity Score at 6 months among interventions. Minimally invasive interventions (EVLA-1470, P < .001; EVLA-810, P = .02; electrocoagulation, P = .006) demonstrated a faster return to normal activities compared with HL&S. In terms of complications, HL&S showed higher proportion of ecchymosis (76.37%) and infection (2.35%), whereas ablation procedures demonstrated higher proportion of skin pigmentation (4.34%-11.41%) across interventions. CONCLUSIONS: In individuals with Clinical-Etiology-Anatomy-Pathophysiology stages C2 to C5 disease, HL&S offer higher long-term freedom from failure and Venous Clinical Severity Score improvement, whereas minimally invasive interventions offer faster short-term recovery. These findings provide evidence to ensuring recommendations address both long-term efficacy and patient-centered short-term outcomes.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Aldian FM, Sembiring YE, Visuddho V, et al. Network meta-analysis of randomized controlled trials evaluating long-term outcomes of interventional approaches for great saphenous vein insufficiency. J Vasc Surg Venous Lymphat Disord. 2026. PMID: 42297210. doi:10.1016/j.jvsv.2026.102553

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。